Immunotherapy has been shown to be beneficial in the first- and second-line setting for multiple solid tumor types. The quickly changing landscape of available therapies and indications can make selection and use of immunotherapies challenging. Additionally, the understanding of combination treatments and management of immune-related adverse reactions is quickly evolving.
Supported by an independent educational grant from
AstraZeneca Pharmaceuticals LP
Steering Committee Chair
Assistant Professor of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, United States
Professor of Medicine, Aix-Marseille University, Marseille, France
Assistant Professor, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Professor of Medicine; Director of Genitourinary Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, United States
Associate Professor of Medicine; Chief of Medical Oncology, National Kapodistrian University of Athens Medical School, Attikon University Hospital, 2nd Dept. of Internal Medicine, Propaedeutic Research Institute, Athens, Greece
Deputy Director, Immunotherapeutics Group; Assistant Attending, Gastrointestinal Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States